Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a controlled clinical trial.

The effect of nicotine absorbed transdermally from a patch (TNS) and from cigarette smoking on insulin secretion and action in Type 2 diabetes has been compared.

The subjects were investigated 12 h after their last cigarette or application of one patch of TNS 30 cm2 or TNS placebo, or whilst smoking their usual cigarette.

Who Took Part

The study group was 2 patients.

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a double-blind, placebo-controlled and crossover study.

Blinding on both sides kept the patients and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

In the crossover set-up each of the patients took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Hydroxybutyrates, Insulin and Insulin Secretion.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of Therapeutic nicotine (patch, non-peptide) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1992 (European journal of clinical pharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.